RP-HPLC Strategies for The Quantification of Linezolid: A Review

This review will discuss the mechanisms, resistance patterns and clinical use of Linezolid, which is the first oxazolidinone antibiotic. Among the important approaches is the analysis of the
ability of Linezolid to inhibit the synthesis of bacterial proteins targeting the 23S rRNA of the 50S
subunit of the ribosome, thus interfering with the initiation of the protein synthesis process. It further
reviews the evolution of Linezolid resistance with specific regard to mutation of 23S rRNA and uL3
and uL4 protein, which undermines the activity of the drug despite these elements being physically
far apart. Key outcomes include the clinical application of Linezolid in the intensive care unit in
managing the infection that is caused by methicillin-resistant Staphylococcus aureus as well as
vancomycin-resistant enterococci. These are hospital-acquired infections that are normally resistant
to various antibiotics. Linezolid is a very important treatment alternative, especially in eliminating
hospital-acquired infections, especially the ones that are resistant to other medicines. The review
highlights the need to keep track of resistance patterns and make the best of using Linezolid to
ensure its effectiveness in clinical practice.